Returns | 1W : 0.5% , 1M : 30.7%,1Y : 310.6% |
LT :   |
    Long Term Analysis
Fundamentals : Bad
Valuation : Average [Stock is fairly valued] Debt : High |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
WINTAC LTD | 0.5% | 30.7% | 310.6% |
SUN PHARMACEUTICAL INDUSTRIES LTD | 0.4% | 7% | 51.4% |
DR REDDYS LABORATORIES LTD | -4.4% | -8.8% | 40% |
DIVIS LABORATORIES LTD | -2.5% | -1.3% | 61.2% |
CIPLA LTD | 0.2% | -3.9% | 83.5% |
BIOCON LTD | -1.5% | 5.4% | 24.1% |
AUROBINDO PHARMA LTD | -2.9% | -10% | 71.1% |
LUPIN LTD | 0.2% | -4.7% | 49.7% |
TORRENT PHARMACEUTICALS LTD | -1.3% | -6.9% | 14% |
Ratio | Value |
---|---|
P/E P/B P/S |
-
P/E Calculated based on EPS of -3.05
[ Mar2020 - Standalone Results ] -
P/B Calculated based on Book Value of -8.15
[ Mar2020 - Standalone Results ] 3.51
P/S Calculated based on Revenues of 97.332 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA -19% -22% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |